Items where authors include "Norris, M."

Article

Dark, P., Hossain, A., McAuley, D.F. et al. (543 more authors) (2025) Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-sepsis randomized clinical trial. Journal of the American Medical Association (JAMA), 333 (8). pp. 682-693. ISSN 0098-7484

Slevin, F. orcid.org/0000-0002-7176-904X, Hudson, E.M. orcid.org/0000-0001-8758-7163, Boele, F.W. et al. (25 more authors) (2025) APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health – study protocol paper for a phase III multicentre, open-label randomised controlled trial. BMJ Open, 15 (2). e097810. ISSN 2044-6055

Li, J.A., Sanderson, M., Willett, P. et al. (2 more authors) (2010) Ranking of library and information science researchers: Comparison of data sources for correlating citation data, and expert judgments. Journal of Informetrics , 4 (4). pp. 554-563. ISSN 1751-1577

Proceedings Paper

Walls, G., Horne, A., Harrow, S. et al. (17 more authors) (2025) 3513: ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: interim report from the CONCORDE phase Ib trial (NCT04550104). In: Radiotherapy and Oncology. ESTRO 2025, 02-06 May 2025, Vienna, Austria. , s1395-s1397.

Horne, A., Walls, G., Brown, S. et al. (17 more authors) (2025) An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRIs) in combination with conventional radiotherapy in NSCLC. In: Journal of Thoracic Oncology. European Lung Cancer Congress 2025, 26-29 Mar 2025, Paris, France. Elsevier BV , S150.

Walls, G., Horne, A., Franks, K. et al. (23 more authors) (2025) 255 An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRis) in combination with conventional radiotherapy in NSCLC. In: Lung Cancer. 23rd BTOG Annual Conference 2025, 03-05 Mar 2025, Belfast, Northern Ireland. Elsevier BV , p. 108364.

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .

Horne, A., Brown, S., Gilbert, A. et al. (16 more authors) (2024) Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm. In: Radiotherapy and Oncology. ESTRO 2024, 03-07 May 2024, Glasgow, UK. , S1652-S1655.